Corrigendum to: Revolutionizing cancer treatment? A conversation on the potential of personalized cancer vaccines

In the version of this Interview initially published, Roy de Souza expressed his opinion on the challenges companies have faced in the development of personalized cancer vaccines (Immuno-Oncology Insights 2024; 5(1), 65–74; pp 68–69); however, this has since altered. 

To reflect this change, we have amended the HTML and PDF versions of this article as of May 30, 2024 and which may be accessed here.